全文获取类型
收费全文 | 46篇 |
免费 | 10篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 1篇 |
基础医学 | 2篇 |
临床医学 | 9篇 |
内科学 | 18篇 |
神经病学 | 3篇 |
特种医学 | 1篇 |
外科学 | 6篇 |
综合类 | 3篇 |
预防医学 | 3篇 |
药学 | 1篇 |
肿瘤学 | 7篇 |
出版年
2021年 | 4篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 2篇 |
2016年 | 2篇 |
2015年 | 4篇 |
2014年 | 3篇 |
2013年 | 3篇 |
2012年 | 2篇 |
2011年 | 2篇 |
2010年 | 1篇 |
2009年 | 2篇 |
2008年 | 3篇 |
2007年 | 9篇 |
2006年 | 2篇 |
2005年 | 5篇 |
2004年 | 4篇 |
2003年 | 1篇 |
2002年 | 3篇 |
1991年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有56条查询结果,搜索用时 15 毫秒
11.
12.
13.
Trifilio S Pennick G Pi J Zook J Golf M Kaniecki K Singhal S Williams S Winter J Tallman M Gordon L Frankfurt O Evens A Mehta J 《Cancer》2007,109(8):1532-1535
BACKGROUND: Low voriconazole levels have been associated with a higher failure rate in patients with confirmed fungal infections. METHODS: Steady-state plasma trough voriconazole levels were measured after at least 5 days of therapy in 87 patients with hematologic malignancies on 201 separate occasions (1-5 levels per patient; median, 2). Most patients (90%) had undergone allogeneic hematopoietic stem cell transplantation. The daily voriconazole dose, administered in 2 divided doses, was 200 mg (n = 4), 400 mg (n = 151), 500 mg (n = 20), 600 mg (n = 18), and 800 mg (n = 8); corresponding to 2.0-16.3 (median, 5.4) mg/kg. Plasma voriconazole levels were 0-12.5 microg/mL (median, 1.2). Voriconazole was undetectable (<0.2 mug/mL) in 15%. RESULTS: The correlation between dose and levels was weak (r = 0.14; P = .045). The median absolute daily drug dose (400 mg) was identical in groups of patients with levels of 0, 0.2 to 0.5, >0.5 to 2.0, >2.0 to 5.0, and >5.0. Whereas the daily drug dose in mg/kg was significantly higher when the levels were >5.0 microg/mL, there was no consistent relation between dose and level below that threshold. In adult patients getting standard doses of voriconazole orally, the drug levels are highly variable. Based on limited available data, between a quarter and two-thirds of these levels could potentially be associated with a lower likelihood of response or a higher likelihood of failure. CONCLUSIONS: Future voriconazole studies should incorporate prospective therapeutic drug monitoring and consideration should be given to checking levels in patients receiving the drug for confirmed, life-threatening fungal infections. 相似文献
14.
Bennett CL Evens AM Andritsos LA Balasubramanian L Mai M Fisher MJ Kuzel TM Angelotta C McKoy JM Vose JM Bierman PJ Kuter DJ Trifilio SM Devine SM Tallman MS 《British journal of haematology》2006,135(5):642-650
Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) and granulocyte colony-stimulating factor (G-CSF) promote haematopoietic progenitor cell maturation. We reviewed the findings for healthy volunteers/donors who developed haematological malignancies following PEG-rHuMGDF or G-CSF administration. Information was reviewed for three of 538 volunteers who received PEG-rHuMGDF in clinical trials and two of 200 donors who underwent G-CSF mobilised stem cell harvesting procedures for sibling stem cell transplants. Mantle cell, diffuse large B-cell lymphoma and chronic lymphocytic leukaemia were diagnosed 1-5 years after PEG-rHuMGDF exposure among three volunteers. For one patient, thrombocytopenia due to autoantibodies to PEG-rHuMGDF developed shortly after PEG-rHuMGDF administration and persisted until chemotherapy was administered. All three achieved complete remission, although one patient relapsed. Acute myeloid leukaemia was diagnosed 4 and 5 years after G-CSF mobilisation in two donors who underwent peripheral blood stem cell donation for sibling allogeneic haematopoietic stem cell transplantation. Following intensive chemotherapy, one died from acute leukaemia and the second is in complete remission. Controversy exists over the appropriateness of administering haematopoietic growth factors to healthy individuals. While a causal relationship with haematological malignancies cannot be demonstrated, long-term follow-up among healthy individuals who receive haematopoietic growth factors is needed. 相似文献
15.
16.
Lynnette M. Henderson Paul J. Yoder Marygrace E. Yale Andrea McDuffie 《International journal of developmental neuroscience》2002,20(3-5):449-458
We examined the longitudinal relationships between power data in two bands (i.e. 4-6 and 6-9Hz) of electrical activity in the brain at 14 months, as measured by background electroencephalograms (EEG), with protodeclarative and protoimperative pointing at 18 months, as measured by the Early Social Communication Scales (ESCS), [Mundy et al., ESCS: A Preliminary Manual for the Abridged Early Social Communication Scales, 1996, unpublished manual] (n=27). EEGs were recorded from 64 sensors using the Electrical Geodesics (EGI) system's dense array sensor nets. Multivariate permutation testing (MPT), which controlled for experiment-wise error due to multiple significance tests, revealed significant correlations between log-transformed power in the frontal region at 14 months and protodeclarative, but not protoimperative, pointing at 18 months. 相似文献
17.
Steven M. Trifilio Marc Scheetz Jayme Borensztajn Jayesh Mehta 《Clinical transplantation》2013,27(1):154-161
Cyclosporine (CSA) is an immunosuppressant used for the prevention of graft rejection and graft‐versus‐host disease (GVHD) during hematopoietic stem cell transplantation. Therapeutic drug monitoring (TDM) is recommended to ensure efficacy and prevent toxicity. Several immunoassay assay are commercially available for measuring CSA drug concentrations. Differences in the cross‐reactive metabolites measured by specific immunoassay tests contribute to the significant lack of specificity which has been reported between immunoassays and high performance liquid chromatography (HPLC) test results. Inter‐assay test results can affect interpretation of CSA drug concentrations and potentially compromise patient outcomes. The current study analyzed 72 paired HPLC‐monoclonal TDX (TDXm) CSA drug concentrations and calculated a clinically reliable correction factor which could be applied to HPLC‐TDXm results for TDM. A unique concordance–discordance simulation model was utilized to validate the correction factor for clinical use. 相似文献
18.
Ciprofloxacin vs levofloxacin for prophylaxis during hematopoietic stem‐cell transplantation
下载免费PDF全文
![点击此处可从《Clinical transplantation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
The objective of the current retrospective study was to compare differences in rate of breakthrough infections for ciprofloxacin vs levofloxacin prophylaxis in autologous hematopoietic stem‐cell transplant (HSCT) patients treated for multiple myeloma. This was a retrospective, cohort study comparing autologous HSCT recipients treated for multiple myeloma who received ciprofloxacin prophylaxis vs levofloxacin prophylaxis. A total of 297 patients, 143 levofloxacin‐ and 154 ciprofloxacin‐treated were included. There was a significantly higher incidence of bloodstream infections in the ciprofloxacin group (24/154) compared to the levofloxacin group (10/143), P = .03, primarily caused by a statistically higher incidence of gram‐positive bloodstream infections (ciprofloxacin [21/154] vs levofloxacin [8/143]; P < .01). Clinically relevant differences exist between fluoroquinolone agents used for prophylaxis. Levofloxacin prophylaxis was more effective than ciprofloxacin prophylaxis to reduce the incidence of bloodstream infections in this study. 相似文献
19.
Gorski E Esterly JS Postelnick M Trifilio S Fotis M Scheetz MH 《Antimicrobial agents and chemotherapy》2011,55(1):184-189
The approved treatment dose of intravenous voriconazole is a weight-based dose of 4 mg/kg of body weight twice daily; the approved oral dosing is fixed at 200 mg twice daily. In our institution, patients frequently receive oral high-dose voriconazole at 4 mg/kg twice daily. It is unknown if higher doses are associated with increased hepatotoxicity. A retrospective cohort study of patients treated with oral voriconazole for presumed invasive fungal infection for ≥7 days was completed. Patients receiving a fixed dose (i.e., labeled dose) were frequency matched and compared to those receiving a weight-based dose (i.e., high dose). The primary endpoint of hepatotoxicity was evaluated by using NCI Common Terminology Criteria (CTC) and components of liver enzymes measuring >3× the upper limit of normal (ULN) and >5× baseline measurements. Secondary endpoints included an incidence of other adverse drug events. Twenty-five labeled-dose and 84 high-dose voriconazole patients were studied. Liver enzyme abnormalities were similar between groups, with the exception of labeled-dose patients experiencing more alkaline phosphatase (ALP) CTC >2× the baseline (P = 0.02) and ALP levels >3× the ULN (P = 0.02). Treatment with high dose was associated with the discontinuation of voriconazole for practitioner attribution of adverse drug events (P = 0.03), although reasons varied and no commonality of biomarker abnormality was identified. Multivariate analysis revealed that the duration of therapy and higher mg/kg total daily doses as interval variables were predictive of some hepatotoxicity outcomes. No difference existed in liver abnormalities for high-dose voriconazole; however, higher mg/kg doses and a longer duration of therapy may be associated with hepatotoxicity. 相似文献
20.
Jessica K. Altman Alfred Rademaker Elizabeth Cull Bing Bing Weitner Yishai Ofran Todd L. Rosenblat Augustin Haidau Jae H. Park Sharona Lee Ram James M. Orsini Jr. Sonia Sandhu Rosalind Catchatourian Steven M. Trifilio Nelly G. Adel Olga Frankfurt Eytan M. Stein George Mallios Tony Deblasio Joseph G. Jurcic Stephen Nimer LoAnn C. Peterson Hau C. Kwaan Jacob M. Rowe Dan Douer Martin S. Tallman 《Leukemia research》2013
We hypothesized that the high early death rate (EDR) due to bleeding in acute promyelocytic leukemia (APL) is in part attributable to delays in all- trans retinoic acid (ATRA). We conducted a retrospective analysis of the timing of ATRA administration. 204 consecutive patients with newly diagnosed APL between 1992 and 2009 were identified. The EDR was 11%. 44% of early deaths occurred in the first week. Hemorrhage accounted for 61% of early deaths. ATRA was ordered the day APL was suspected in 31% of patients. Delays in ATRA administration led to increases in the percentage of early deaths from hemorrhage. 相似文献